These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1499005)

  • 21. The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression.
    Jann MW; Cohen LJ
    Drug Metabol Drug Interact; 2000; 16(1):39-67. PubMed ID: 10820582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
    Desta Z; Zhao X; Shin JG; Flockhart DA
    Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.
    Landi MT; Ceroni M; Martignoni E; Bertazzi PA; Caporaso NE; Nappi G
    Adv Neurol; 1996; 69():61-72. PubMed ID: 8615186
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imipramine: a model drug for P450 research.
    Brøsen K; Skjelbo E; Nielsen KK
    Methods Enzymol; 1996; 272():177-86. PubMed ID: 8791776
    [No Abstract]   [Full Text] [Related]  

  • 27. [Human biodiversity and its effects on the pharmacological variability: CYP2D6 and NAT2 enzymes in Amerind populations of Panama, Colombia and Costa Rica].
    Jorge LF; Arias TD
    Rev Med Panama; 1995 Sep; 20(3):98-107. PubMed ID: 8668827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cytochrome pharmacogenetics applied to the prescription of antidepressants: Instructions for use].
    Baldacci A; Saguin E; Annette S; Lahutte B; Colas MD; Delacour H
    Encephale; 2022 Aug; 48(4):462-471. PubMed ID: 35331467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies.
    Eap CB; Jaquenoud Sirot E; Baumann P
    Ther Drug Monit; 2004 Apr; 26(2):152-5. PubMed ID: 15228156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Debrisoquine hydroxylase polymorphism in Leber's hereditary optic neuropathy.
    Chalmers RM; Bandmann O; Harding AE
    J Neurol Neurosurg Psychiatry; 1996 May; 60(5):588. PubMed ID: 8778272
    [No Abstract]   [Full Text] [Related]  

  • 31. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
    Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
    Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes.
    Bloomer JC; Woods FR; Haddock RE; Lennard MS; Tucker GT
    Br J Clin Pharmacol; 1992 May; 33(5):521-3. PubMed ID: 1388041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Narcotic analgesics and debrisoquine polymorphism.
    Lavrijsen KL; Heykants JJ
    Anesthesiology; 1989 Sep; 71(3):474-5. PubMed ID: 2570539
    [No Abstract]   [Full Text] [Related]  

  • 34. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.
    Spigset O; Granberg K; Hägg S; Norström A; Dahlqvist R
    Eur J Clin Pharmacol; 1997; 52(2):129-33. PubMed ID: 9174682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition and induction of cytochrome P450 isozymes after repetitive administration of imipramine in rats.
    Masubuchi Y; Takahashii C; Fujio N; Horie T; Suzuki T; Imaoka S; Funae Y; Narimatsu S
    Drug Metab Dispos; 1995 Sep; 23(9):999-1003. PubMed ID: 8565792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.
    Quaranta S; Dupouey J; Colle R; Verstuyft C
    Therapie; 2017 Apr; 72(2):311-318. PubMed ID: 28237405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.
    Borg KO; Johnsson G; Jordö L; Lundborg P; Rönn O; Welin-Fogelberg I
    Acta Pharmacol Toxicol (Copenh); 1979 Sep; 45(3):198-205. PubMed ID: 506742
    [No Abstract]   [Full Text] [Related]  

  • 38. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
    Spigset O; Hedenmalm K; Dahl ML; Wiholm BE; Dahlqvist R
    Acta Psychiatr Scand; 1997 Nov; 96(5):379-84. PubMed ID: 9395157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine.
    Caporaso NE; Shaw GL
    Arch Intern Med; 1991 Oct; 151(10):1985-92. PubMed ID: 1681790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Awareness of potential drug interactions may aid avoidance.
    DeVane CL; Gill HS; Markowitz JS; Carson WH
    Ther Drug Monit; 1997 Jun; 19(3):366-7. PubMed ID: 9200782
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.